羚锐制药
(600285)
| 流通市值：129.65亿 | | | 总市值：130.56亿 |
| 流通股本：5.63亿 | | | 总股本：5.67亿 |
| 报告期 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,506,780,833.45 | 1,700,662,495.56 | 788,648,249.06 | 3,001,862,213.98 |
| 营业收入 | 2,506,780,833.45 | 1,700,662,495.56 | 788,648,249.06 | 3,001,862,213.98 |
| 二、营业总成本 | 1,988,216,290.95 | 1,347,263,731.98 | 622,764,688.53 | 2,584,417,121.57 |
| 营业成本 | 636,043,447.15 | 419,755,054.27 | 185,065,263.91 | 832,113,813.97 |
| 税金及附加 | 34,585,063.98 | 23,646,629 | 10,919,805.55 | 40,916,245.94 |
| 销售费用 | 1,148,874,536.12 | 791,461,516.73 | 376,349,019.13 | 1,443,500,681.9 |
| 管理费用 | 126,718,482.8 | 84,283,704.81 | 35,044,898.68 | 169,408,379.42 |
| 研发费用 | 66,451,637.23 | 43,284,877.49 | 21,205,202.59 | 125,065,576.02 |
| 财务费用 | -24,456,876.33 | -15,168,050.32 | -5,819,501.33 | -26,587,575.68 |
| 其中:利息费用 | 1,234,214.26 | 972,168 | 2,364,729.09 | 774,624.73 |
| 其中:利息收入 | 26,168,606.54 | 16,318,876.29 | 6,559,323.78 | 27,952,057.04 |
| 加:公允价值变动收益 | 58,708.85 | 38,000.16 | 42,040.88 | 5,925,973.03 |
| 加:投资收益 | 10,776,690.02 | 6,648,743.76 | 4,145,174.76 | 58,655,487.59 |
| 资产处置收益 | 47,499.98 | 47,499.98 | -1,192.78 | 24,593.04 |
| 资产减值损失(新) | -196,053.37 | -200,106.17 | -32,280.82 | -170,504.65 |
| 信用减值损失(新) | -5,559,117.02 | -4,709,105.56 | -2,500,773.53 | -3,514,051.91 |
| 其他收益 | 15,404,612 | 10,261,354.87 | 3,093,467.48 | 38,754,892.51 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 539,096,882.96 | 365,485,150.62 | 170,629,996.52 | 517,121,482.02 |
| 加:营业外收入 | 318,945.59 | 275,556.15 | 43,129.93 | 809,809.91 |
| 减:营业外支出 | 1,539,014.69 | 1,307,344.14 | 720,195.26 | 896,763.69 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 537,876,813.86 | 364,453,362.63 | 169,952,931.19 | 517,034,528.24 |
| 减:所得税费用 | 71,690,864.7 | 47,426,097.84 | 25,772,632.92 | 51,703,330.98 |
| 六、净利润 | 466,185,949.16 | 317,027,264.79 | 144,180,298.27 | 465,331,197.26 |
| 持续经营净利润 | 466,185,949.16 | 317,027,264.79 | 144,180,298.27 | 465,331,197.26 |
| 归属于母公司股东的净利润 | 466,182,042.18 | 316,981,106.19 | 144,246,384.9 | 465,330,827.06 |
| 少数股东损益 | 3,906.98 | 46,158.6 | -66,086.63 | 370.2 |
| (一)基本每股收益 | 0.83 | 0.56 | 0.26 | 0.84 |
| (二)稀释每股收益 | 0.82 | 0.56 | 0.25 | 0.82 |
| 八、其他综合收益 | 2,874,703.27 | -155,901.03 | 204,257.86 | 20,710,132.07 |
| 归属于母公司股东的其他综合收益 | 2,805,368.63 | -186,542.77 | 191,911.42 | 20,655,424.21 |
| 九、综合收益总额 | 469,060,652.43 | 316,871,363.76 | 144,384,556.13 | 486,041,329.33 |
| 归属于母公司股东的综合收益总额 | 468,987,410.81 | 316,794,563.42 | 144,438,296.32 | 485,986,251.27 |
| 归属于少数股东的综合收益总额 | 73,241.62 | 76,800.34 | -53,740.19 | 55,078.06 |
| 公告日期 | 2023-10-28 | 2023-08-10 | 2023-04-26 | 2023-04-26 |
| 审计意见(境内) | | | | 标准无保留意见 |